

HeartLung Technologies Presented AI-CAC™ and AI-CVD™ Research Studies at the American Heart Association 2024 Conference

Innovative AI-enabled research studies led by HeartLung's founder Dr. Morteza Naghavi show life-saving potential in primary prevention of cardiovascular disease

CHICAGO, TX, UNITED STATES, November 18, 2024 /


EINPresswire.com/ -- HeartLung Technologies is thrilled to announce that seven of its scientific research studies were presented at the 2024 Annual Scientific Sessions of the American Heart Association that coincided with the 100th anniversary of the Heart Association.

The event, which took place on November 16-18, 2024, brought a large number of cardiovascular specialists, including physicians, nurses, research scientists, and industry experts, to Chicago.

The presentations by HeartLung Technologies showcase cutting-edge research and innovations that have the potential to significantly impact cardiovascular healthcare in the field of primary prevention. The following studies have been accepted for presentations:

The AHA24 presentations by HeartLung Technologies showcase cutting-edge research and innovations that have the potential to significantly impact cardiovascular healthcare. The following studies have been accepted for presentations:

1. [AI-CVD](#): Artificial Intelligence-Enabled Opportunistic Screening of Coronary Artery Calcium



Computed Tomography Scans for Predicting CVD Events and All-Cause Mortality: The Multi-Ethnic Study of Atherosclerosis (MESA)

2. Incorporating AI-enabled Left Atrial Volume Measurement from Coronary Artery Calcium Scans (AI-CAC) to CHA2DS2s-VASc Risk Score Improves Stroke Prediction in the Asymptomatic Population: The Multi-Ethnic Study of Atherosclerosis

3. AI-enabled Cardiac Chambers Volumetry in Coronary Artery Calcium Scans (AI-CAC) vs. ASCVD Pooled Cohorts Equation and PREVENT Risk Scores: The Multi-Ethnic Study of Atherosclerosis


4. Coronary Artery Calcium Scans Powered by Artificial Intelligence (AI-CAC) Predicts Atrial Fibrillation and Stroke Comparably to Cardiac Magnetic Resonance Imaging: The Multi-Ethnic Study of Atherosclerosis (MESA)

5. Automated Left Ventricular Volumetry using Artificial Intelligence in Coronary Calcium Scans (AI-CAC) Predicts Heart Failure Comparably to Cardiac MRI and Outperforms NT-proBNP: The Multi-Ethnic Study of Atherosclerosis (MESA)


6. AI-enabled bone mineral density (AutoBMD AI) measurement in coronary artery calcium (CAC) scans associated with high CAC score independently of conventional risk factors: Multi-Ethnic Study of Atherosclerosis (MESA)

7. AI-enabled Cardiac Chambers Volumetry in Non-Contrast Cardiac CT scans (AI-CAC) Detects HFrEF vs. HFpEF

List of AHA 2024 Abstracts Coauthors:



AI-CAC with calcium score, calcified plaque characterization, and cardiac chambers volumes.



AI-CVD vs PREVENT Risk Score

Morteza Naghavi, MDa, Anthony P. Reeves, PhDb, Kyle Atlas, BSa, Chenyu Zhang, MSa, Thomas Atlas, MDc, Claudia Henschke, PhD., MDd, David Yankelevitz, MDd, Matthew J. Budoff, MDe, Dong Li, PhD, Wenjun Fan, MD, PhDm, Ruilin Yu, MPHn, Andrea Branch, MDd, Ning Ma, PhDd, Rowena Yip, PhDd, Sion K. Roy, MDe, Khurram Nasir, M.Df, Sabee Molloy, PhDg, Zahi Fayad, PhDf, Michael V. McConnell, MD, MSEEh, Ioannis Kakadiaris, MDi, Javier Zuelueta, MDd, David J. Maron, MDh, Jagat Narula, MD, PhDi, Prediman Shah, MDo, Kim Williams, MDj, Daniel Levy, M.Dk, Nathan D. Wong, PhDl.

a. HeartLung.AI, Houston, TX, 77021

b. Department of Electrical and Computer Engineering, Cornell University, Ithaca, NY 14853

c. Tustin Teleradiology, Tustin, CA 92780

d. Mount Sinai Hospital, New York, NY 10029

e. The Lundquist Institute, Torrance, CA 90502

f. Houston Methodist Hospital, Houston, TX 77030

g. Department of Radiology, University of California Irvine, CA 92697

h. Department of Medicine, Stanford University School of Medicine, Stanford, CA, 94305

i. The University of Texas Health Science Center at Houston, TX, 77030

j. University of Louisville, Louisville, KY



Dr. Morteza Naghavi, founder of HeartLung Technologies



November 17
12:30 - 1:30 PM CST

HeartLung Technologies
BOOTH #2654

Meet Dr. Morteza Naghavi and Dr. Nathan Wong
The coauthors of AI-CAC and AI-CVD studies presented
at the AHA'24 Annual Scientific Sessions in Chicago

AHA
2024



Dr. Nathan Wong



Dr. Morteza Naghavi

American Heart Association Scientific Sessions
McCormick Place Convention Center | Chicago, IL

Meet Dr. Naghavi and Dr. Wong Co-Authors of AI-CVD
at AHA 2024

k. Population Sciences Branch, Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, 20824

l. [Heart Disease](#) Prevention Program, Division of Cardiology, University of California Irvine, CA 92697

m. Department of Epidemiology & Biostatistics, University of California Irvine, CA 92697

n. Department of Epidemiology, University of California, Los Angeles, CA 90095

o. Cedars-Sinai Medical Center, Los Angeles, CA, 90048

Every year AHA's scientific review committee selects presentations through a rigorous peer-review process. The fact that HeartLung Technologies received acceptance for 7 presentations speaks volume for the scientific power of HeartLung's outstanding team. The AI-CAC™ and AI-CVD™ studies demonstrate the company's ongoing commitment to advancing cardiovascular health in preventive cardiology through the power of AI.

Dr. Morteza Naghavi, the founder and president of HeartLung Technologies expressed his pride in the team's accomplishments "I'm so proud of our team at HeartLung and our esteemed academic collaborators" said Dr. Naghavi. "Our goal is to advance preventive cardiology with AI."

About American Heart Association

The American Heart Association (AHA) is a nonprofit organization in the United States that funds cardiovascular medical research, educates consumers on healthy living and fosters appropriate cardiac care in an effort to reduce disability and deaths caused by cardiovascular disease and stroke. They are known for publishing guidelines on cardiovascular disease and prevention, standards on basic life support, advanced cardiac life support (ACLS), pediatric advanced life support (PALS), and in 2014 issued the first guidelines for preventing strokes in women.[1] The American Heart Association is also known for operating a number of highly visible public service campaigns starting in the 1970s, and also operates several fundraising events. Originally formed in Chicago in 1924,[2][3] the American Heart Association is currently headquartered in Dallas, Texas. It was originally headquartered in New York City.[2][3] The American Heart Association is a national voluntary health agency.[4] The mission of the organization, updated in 2018, is "To be a relentless force for a world of longer, healthier lives." [5] The organization's work can be divided into five key areas: research; heart and brain health; health equity; advocacy; and professional education and development. This year AHA celebrated its 100th year anniversary in Chicago along with the 2024 Annual Scientific Sessions where HeartLung Technologies presented its AI-CAC™ and AI-CVD™ research studies.

About HeartLung Technologies

HeartLung Technologies aims to help people live long by eliminating preventable deaths caused by heart attacks, lung cancer, osteoporosis, chronic pulmonary obstructive disease (COPD), fatty liver disease, and other deadly medical conditions. HeartLung's team of industry-leading physicians and engineers are dedicated to increasing people's life-span and health-span by starting with taking out America's most deadly killers: heart disease and lung cancer. HeartLung is innovating for the millions of Americans and many more worldwide who can benefit from early detection of preventable fatal diseases. HeartLung.AI is a portfolio company of American Heart Technologies (AHT) founded by Dr. Morteza Naghavi, a leader in preventive cardiology and health-tech, former faculty of Texas Heart Institute and University of Texas in 2007. AHT was established as a vehicle for commercialization of innovative healthcare solutions, three of which received FDA approval and were commercialized under portfolio companies Endothelix Inc., and CardioNexus Corp, and HeartLung Corp.

For more information about HeartLung Technologies, please visit www.heartlung.ai. and www.americanhearttechnologies.com

Marlon Montes
HeartLung Corporation
+1 310-510-6004

[email us here](#)

Visit us on social media:

[Facebook](#)

[X](#)

[LinkedIn](#)

[Instagram](#)

[YouTube](#)

[Other](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/761630185>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.